spacer
home > ebr > summer 2017 > in your genes
PUBLICATIONS
European Biopharmaceutical Review

In Your Genes

In April 2017, the FDA formally approved the sale of direct-to-consumer genetic testing for 10 disease indications and established a framework for future approvals. This opens up the field to consumer genetic tests that are both accurate in their readout and significant in their interpretation. It places the US market on the same playing field as Canada and UK – but the move is not without controversy.

Advances in genomics have stimulated great interest as a tool for drug discovery, as a means of disease diagnosis and treatment and as an additional way to make sense of individual prognoses. Particularly in the consumer health arena, breathtaking advances in science have captured the public imagination as a possible way to predict future health outcomes. As a sidebar, the ancestry interpretation of personal genomics has become very popular.

The recent FDA move concludes four years of restrictions placed on claims and product offerings by the personal genomics company 23andMe. This was a time to validate the accuracy of the lab work, scientific significance and clinical relevance and to address concerns about the consumer-facing documentation and interpretation. Doctors had often been faced with difficult patient questions like, ‘how much does this increase my risk?’

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Emile Bellott is a member of the EBR Industry Advisory Board, and an industry consultant, with experience in drug discovery, development and pharmaceutical outsourcing.
spacer
Emile Bellott
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

The Latest Innovations in HPAPI Manufacturing Technologies

SMi’s inaugural Highly Potent Active Pharmaceutical Ingredients USA Conference, will focus on the latest innovative manufacturing technologies with a special spotlight presentation on effective and safe containment solutions for biologics based HPAPIs, along with cleaning and cross contamination requirements.
More info >>

White Papers

The current and future role of the medical oncologist in the professional care for cancer patients: a position paper by the European Society for Medical Oncology

European Society for Medical Oncology (ESMO)

  The number of cancer patients in Europe is rising and significant advances in basic and applied cancer research are making the provision of optimal care more challenging. The concept of cancer as a systemic, highly heterogeneous and complex disease has increased the awareness that quality cancer care should be provided by a multidisciplinary team (MDT) of highly qualified healthcare professionals. Cancer patients also have the right to benefit from medical progress by receiving optimal treatment from adequately trained and highly skilled medical professionals. Built on the highest standards of professional training and continuing medical education, medical oncology is recognised as an independent medical specialty in many European countries.
More info >>

 
Industry Events

CPhI & P-MEC India

26-28 November 2019, India Expo Centre, Greater Noida, Delhi NCR, India

As the pharma industry looks increasingly towards India for high quality, low cost pharma solutions, CPhI & P-MEC India is the ideal event for companies wanting to pick up on the latest trends and innovations the market has to offer. At CPhI & P-MEC India, you will meet the movers and shakers from India's pharma machinery, technology and ingredients industries, giving you a competitive advantage that will help grow your business.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement